Access program for valemetostat in peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This program provides access to valemetostat, an investigational pill, for people with certain types of peripheral T-cell lymphoma (PTCL) that have not responded to or returned after at least two prior treatments. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of peripheral T-cell lymphoma (PTCL) that has come back or not responded to at least two prior treatments.
- If you have a specific subtype called ALCL, you must have received the drug brentuximab vedotin before.
- Your overall health is reasonably good (able to do light activity).
- Your liver, kidneys, and bone marrow are working well enough (the doctor will check with lab tests).
- You agree to use highly effective birth control during treatment and for 3 months after the last dose, and not donate eggs or sperm during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental virus therapy given through a vein for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The virus is designed to infect and destroy cancer cells. Some patients may also receive another drug called cemiplimab as part of a combination group.
This study tests a new combination therapy with a drug called tazemetostat for people with peripheral T-cell lymphoma that has relapsed (come back) or is refractory (did not respond to previous treatment). The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of two drugs (valemetostat and atezolizumab) for people with extensive-stage small cell lung cancer who have already responded to initial chemo-immunotherapy. The goal is to see if adding valemetostat can keep the cancer from growing longer.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a new experimental antibody therapy for people with certain types of peripheral T-cell lymphoma that have not responded to or have come back after prior treatment. The study aims to see if the treatment is safe and effective.
This program provides access to AMTAGVI, a personalized cell therapy for melanoma, for patients whose manufactured product did not meet commercial release standards but was deemed safe. It aims to offer treatment when no other options are available.
Hear when a new Adult T-cell Leukemia/Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.